Lots of drugmakers see Africa as a market that over time can produce some substantial business. But GlaxoSmithKline is not just manufacturing and selling drugs there. It is going one better with a new "open lab" R&D facility to let African researchers work on the drugs needed by Africans for noncommunicable diseases.
AstraZeneca has struck up a partnership with the Shenzhen University Health Science Center in Shanghai to collaborate on preclinical work for chronic kidney disease treatments, a growing problem among China's aging population.
In the nearly 40 years since scientists first nailed down the Ebola virus, drug researchers have yet to commercialize an effective therapy for the deadly disease, a problem made worse by a lack of commercial promise and the relative rarity of outbreaks.
As more and more drugmakers set sights on China through partnerships and acquisitions, Sino-American biotech RuiYi is taking a more direct approach, raising $15 million in venture cash to develop novel drugs in the country, for the country.
The market may do what regulators around the world have been unable to achieve so far: It may make quality and consistent supply the focus for generics buyers over price.
GE Healthcare is going beyond just selling diagnostic imaging products in India to get involved, in part, in the distribution of care. The company will team up with a U.S. cancer healthcare operator to open cancer clinics that will rely on some of its key technology.
GE Healthcare has developed a discount molecular imaging system for cancer detection, intended for physicians practicing personalized medicine in emerging markets--especially India, where the devicemaker got help designing the system.
Drug wholesaler AmerisourceBergen continues its global expansion with an agreement to buy nearly a 20% stake in Brazilian distributor Profarma Distribuidora de Produtos Farmacêuticos (Profarma).
Parexel is stretching its global network of clinical trial supply operations with a new distribution center in Singapore, bringing the facility online to better support studies across the globe.
Indian CRO GVK Biosciences is looking to boost its capabilities in contract manufacturing, planning to build a new plant in its home country while stretching its presence abroad.